SCHEMBL2417360

SCHEMBL2417360

C[Si](C)(C)CC#Cc1cccc(N)c1C#N

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
GAA P10253 1/20 0.33
LMNA P02545 2/20 0.32
POLB P06746 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
KDM1A O60341 1/20 0.31
MAP2K1 Q02750 1/20 0.30
TP53 P04637 1/20 0.30
HPGD P15428 1/20 0.30
HTT P42858 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1702636 0.73 CYP3A4 (0.48) CYP1A2CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL618983 0.72 CYP3A4 (0.39) CYP1A2CYP3A4CYP2C9CYP2C19MAPT
Nitrogen SCHEMBL27862489 0.72 CYP3A4 (0.47) CYP1A2CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL1398115 0.69 ALDH1A1 (0.43) CYP1A2CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL2417697 0.69 CYP3A4 (0.40) CYP1A2CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL27777033 0.65 PNMT (0.39) CYP1A2CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL620321 0.65 KCNH2 (0.43) CYP1A2CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL31208138 0.64 CD44 (0.50) CYP1A2CYP3A4CYP2C19KDM4EALDH1A1
SCHEMBL1143074 0.64 CD44 (0.50) CYP1A2CYP3A4CYP2C19KDM4EALDH1A1
SCHEMBL2417609 0.64 GABRA1 (0.40) CYP3A4MAPTKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2573559-B1 Modulation of chemosensory receptors and ligands associated therewith SENOMYX INC (US) 2019-03-13 EP disclosed
EP-2062050-B1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX INC (US) 2016-05-18 EP disclosed
US-9181276-B2 Modulation of chemosensory receptors and ligands associated therewith SENOMYX, INC. (US) 2015-11-10 US disclosed
US-20140235623-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2014-08-21 US disclosed
US-8633186-B2 Modulation of chemosensory receptors and ligands associated therewith SENOMYX INC. (US) 2014-01-21 US disclosed
EP-2573559-A1 Modulation of chemosensory receptors and ligands associated Senomyx, Inc. (US) 2013-03-27 EP disclosed
EP-2568287-A2 Modulation of chemosensory receptors and ligands associated Senomyx, Inc. (US) 2013-03-13 EP disclosed
US-20110224155-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX INC. (US) 2011-09-15 US disclosed
EP-2062050-A2 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH Senomyx, Inc. (US) 2009-05-27 EP disclosed
WO-2008154221-A2 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235623-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH TAS2R30, TAS2R50, TAS2R1 CYP1A2 4533/4885CYP3A4 3308/4885CYP2C9 4695/4885
US-20110224155-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH TAS2R30, TAS2R50, TAS2R1 CYP1A2 4533/4885CYP3A4 3308/4885CYP2C9 4695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.